Satellos Bioscience Inc ICOTF

Primary Symbol: T.MSCL Alternate Symbol(s): MSCLF

Healthcare Biotechnology

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).

TSX:MSCL - Post by User

Satellos Bioscience Inc

Bullboard Posts

Post by stockgurukingon May 30, 2013 2:31pm

245 Views

Post# 21462302

Cash runway. PT: $1.25

The current cash on hand is ~$4million dollars which when taking into account G&A and the cost of the trial (all of which can be found in the Q1 financials) gives the company cash until Q2-1014 and past the Phase II primary end-point data.

*

Doug Loe at Byron had an update this morning on ICO with a $1.25 target that was positive on the company and the Ophthalmology sector.

Bullboard Posts

From now on, dynaCERT instead of Bitcoin or NVIDIA?